Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.
Joel A Morales-RosadoKashish GoelLingxin ZhangAxel ÅkerblomSaurabh BahetiJohn L BlackNiclas ErikssonLars WallentinStefan JamesRobert F StoreyShaun G GoodmanGregory D JenkinsBruce W EckloffSuzette J BielinskiHugues SicotteStephen JohnsonVeronique L RogerLiewei WangRichard WeinshilboumEric W KleeCharanjit S RihalNaveen L PereiraPublished in: Cardiovascular drugs and therapy (2020)
NGS detected CYP2C19 poor metabolizers and paradoxically greater number of so-called rapid metabolizers in ST cases. Rare deleterious exonic variation occurs in 4%, and potentially disruptive intronic alleles occur in 16% of ST cases. Additional studies are required to evaluate the role of these variants in platelet aggregation and clopidogrel metabolism.
Keyphrases